Table 1.
Clinical data and results of questionnaires and laboratory tests of the three groups of the asthma population
| Characteristics | Asthma status | ||
|---|---|---|---|
| Uncontrolled | Partially controlled | Controlled | |
| Subjects (n) | 48 | 45 | 49 |
| Age (yrs) | 45.7 (17.0) | 46.0 (18.9) | 36.6 (19.3) |
| Males (%) | 44 | 38 | 63 |
| BMI (kg· m−2) | 27.5 (5.5) | 26.1 (5.5) | 24.1 (4.1) |
| Ex-smokers (%) | 17 | 18 | 10 |
| Poor adherence to treatment* (%) | 25 | 42 | 22 |
| Atopy (%) | 87 | 80 | 92 |
| Duration of disease (yrs) | 27.9 (15) | 25.8 (14.1) | 21.9 (13.9) |
| Oral corticosteroids bursts (≥1) in previous year (%) | 40 | 13 | 4 |
| Inhaled corticosteroids (ICS) (%) | 77 | 76 | 49 |
| Low/medium/high doses of ICS** (%) | 27/49/24 | 56/29/15 | 71/17/12 |
| LABA(%) | 63 | 62 | 43 |
| AntiLT (%) | 52 | 58 | 51 |
| LAMA (%) | 13 | 11 | 8 |
| ACT | 15.8 (4.2) | 20.3 (2.5) | 22.7 (2.1) |
| ACQ-7 | 2 (0.9) | 1.2 (0.6) | 0.8 (1.4) |
| AQLQ | 4.7 (1.1) | 5.6 (1) | 6.1 (0.8) |
| FENO (ppb) | 53.2 (39.2) | 53.2 (39.8) | 54.1 (29.4) |
| ECPΓ (µg/L) | 30.2 (30.9) | 38.9 (41.5) | 31.3 (40.5) |
| Total IgEΓ (kU/L) | 593.2 (957.3) | 439 (735.2) | 456.8 (501.4) |
| EosinophilsΓ (10^3/µL) | 0.4 (0.3) | 0.4 (0.5) | 0.3 (0.2) |
Notes: Data are presented as mean (SD) or %. *Morisky-Green. **Equipotent doses of inhaled corticoids according GINA 2012 guidelines. ΓDetermined in peripheral blood.
Abbreviations: LABA, long acting beta agonist; antiLT; antileucotrienes; LAMA, long acting muscarinic agonist; ICS, inhaled corticosteroids; ACT, asthma control test; ACQ-7, asthma control questionnaire-7; AQLQ, asthma quality of life questionnaire; FENO, fractional exhaled oxid nitric; ECP, eosinophil cationic protein.